Focus: NewLimit is a biotechnology company focused on epigenetic reprogramming therapies, headquartered in South San Francisco. The company targets rare diseases using proprietary epigenetic editing technology.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
High-risk, high-reward opportunity suitable for scientists seeking deep technical ownership in emerging epigenetic space, but visibility into funding and timelines is critically limited.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for NewLimit
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NewLimit's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo